Physician profile
Haley Wilson
NPI 1194193607
$751.75
in general payments reported to CMS, 2019-2025
14 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $98.07 · 2023: $15.75 · 2024: $108 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $204.71 | 2021 | |
| Inspire Medical Systems, INC. | $108.33 | 2025 | Inspire |
| Indivior INC. | $74.59 | 2022-2025 | Sublocade |
| Regeneron Healthcare Solutions, INC. | $72.25 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $65.02 | 2024 | |
| Medtronic, INC. | $49.66 | 2022 | |
| Genentech USA, INC. | $33.66 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2025 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $24.37 | 2025 | |
| Optinose US, INC. | $22.31 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.85 | 2025 | Xhance, Nuzyra |
| Amgen INC. | $18.63 | 2025 | Tezspire |
| Phathom Pharmaceuticals, INC. | $17.57 | 2024 | Voquezna |
| Horizon Therapeutics Plc | $15.75 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.